Professional Marketing: Novartis, Epocrates, Cegedim Dendrite and SK&A Information Services

Novartis launched schizophrenia med Fanapt to US physicians, following a May 2009 approval. In October, Novartis acquired US and Canadian commercialization rights to the pill from Vanda, which retains ex-US marketing rights. A long-acting injectable (depot) formulation is being developed.

Mobile clinical-software outfit Epocrates hired Geoffrey Rutledge, MD, PhD, as chief medical officer and EVP, product development. Rutledge, who has held senior-management roles with WebMD and First Consulting Group, will oversee Epocrates' medical-information team and lead the development of new products.

CRM firm Cegedim Dendrite acquired healthcare data provider SK&A Information Services for an undisclosed sum. SK&A maintains a telephone-verifiable database of contact records used by pharma clients for commercial planning and operations. The firm will be branded as SK&A, A Cegedim Company.
You must be a registered member of MMM to post a comment.

A wave of more effective anti-cancer drugs has set the oncology world on fire with enthusiasm. While many hail this as a new era, an equally vocal faction questions the money spent for the value gained. This medical and commercial trend report for marketers of anti-cancer modalities touches on many of the latest shifts that have expedited product launches and otherwise impacted promotion and reimbursement of these drugs. Click here.

Email Newsletters


Pharma continues to struggle with its image. Exhibit A is the public debate around the price of, and access to, new and innovative meds. As countless transformative technologies hit market, has industry done enough to anchor its permission to innovate? To provide a closer look at trends affecting trust over the past year, MM&M presents this e-book, "The 2015 Edelman Trust Barometer." Click here.